Repositioning Generic Drugs: Empirical Findings and Policy Implications
Open Access
- 12 September 2022
- journal article
- research article
- Published by Springer Nature in IIC - International Review of Intellectual Property and Competition Law
- Vol. 53 (9) , 1287-1322
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Extensions of indication throughout the drug product lifecycle: a quantitative analysisDrug Discovery Today, 2016
- Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complexNeuro-Oncology, 2015
- Patents and plausibilityJournal of Intellectual Property Law and Practice, 2013
- Use of medicines for carved out indications - Time for a change in approach?Journal of Commercial Biotechnology, 2013
- Drug Repurposing: Far Beyond New Targets for Old DrugsThe AAPS Journal, 2012
- Systematic Phenotypic Screening for Novel Synergistic Combinations: A New Paradigm for Repositioning Existing Drugs2012
- Opportunities and Challenges Associated with Developing Additional Indications for Clinical Development Candidates and Marketed Drugs2012
- Drug repurposing from an academic perspectiveDrug Discovery Today: Therapeutic Strategies, 2011
- Incentives for Drug Development — The Curious Case of ColchicineNew England Journal of Medicine, 2010
- Impact of Economic, Regulatory, and Patent Policies on Innovation in Cancer ChemopreventionCancer Prevention Research, 2008